Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer

被引：4
作者：
Soares, Adriana [1 ]
Carmo, Rafael [2 ]
Rodrigues, Catarina [3 ]
Grilo, Ines Teles [4 ]
Grande, Enrique [5 ]
机构：
[1] Unidade Local Saude Matosinhos, Med Oncol Dept, Matosinhos, Portugal
[2] Grp Sasse Oncol & Hematol SOnHe, Med Oncol Dept, Campinas, SP, Brazil
[3] Ctr Hosp Entre Douro & Vouga, Med Oncol Dept, Santa Maria Feira, Portugal
[4] Ctr Hosp Tras Os Montes & Alto Douro, Med Oncol Dept, Vila Real, Portugal
[5] MD Anderson Canc Ctr Madrid, Med Oncol Dept, Madrid, Spain
来源：
BLADDER CANCER | 2020年 / 6卷 / 01期
关键词：
Metastatic bladder cancer; immunotherapy; chemotherapy; CISPLATIN-INELIGIBLE PATIENTS; UROTHELIAL CARCINOMA; URINARY-TRACT; SINGLE-ARM; METHOTREXATE; VINBLASTINE; DOXORUBICIN; MULTICENTER; COMBINATION; GEMCITABINE;
D O I：
10.3233/BLC-190260
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Urothelial tumors are one of the most prevalent cancers worldwide. Cisplatin-based chemotherapy has been the standard first-line treatment for metastatic urothelial cancer (mUC). After nearly three decades of limited advances in the treatment, immune checkpoint inhibitors (ICI) are now available. Responses to immunotherapy (TO) may be long lasting and sustained but only occur in 20-30% of patients. Studies have shown that combining IO with different targeted therapies can lead to potentiating effects with promising results. The first result combining ICI plus chemotherapy shows positive outcomes over standard-of-care in first line mUC. The aim of this article is to review the results, the benefits and new challenges that the combination of chemotherapy and IO can bring to patients with metastatic urothelial carcinoma.
引用
收藏
页码：1 / 8
页数：8
相关论文
共 28 条
  • [1] Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
    Antoni, Sebastien
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Znaor, Ariana
    Jemal, Ahmedin
    Bray, Freddie
    [J]. EUROPEAN UROLOGY, 2017, 71 (01) : 96 - 108
  • [2] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    de Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Perini, Rodolfo F.
    Keefe, Stephen M.
    Bajorin, Dean
    Bellmunt, Joaquim
    [J]. LANCET ONCOLOGY, 2017, 18 (11) : 1483 - 1492
  • [3] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    [J]. LANCET, 2017, 389 (10064) : 67 - 76
  • [4] Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
    Bamias, A.
    Tzannis, K.
    Harshman, L. C.
    Crabb, S. J.
    Wong, Y. -N.
    Pal, S. Kumar
    De Giorgi, U.
    Ladoire, S.
    Agarwal, N.
    Yu, E. Y.
    Niegisch, G.
    Necchi, A.
    Sternberg, C. N.
    Srinivas, S.
    Alva, A.
    Vaishampayan, U.
    Cerbone, L.
    Liontos, M.
    Rosenberg, J.
    Powles, T.
    Bellmunt, J.
    Galsky, M. D.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (02) : 361 - 369
  • [5] An update on immunotherapy options for urothelial cancer
    Bilgin, Burak
    Sendur, Mehmet A. N.
    Hizal, Mutlu
    Yalcin, Bulent
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (12) : 1265 - 1274
  • [6] Burtness B., 2019, LANCET LONDON ENGLAN, P1
  • [7] International Variations in Bladder Cancer Incidence and Mortality
    Chavan, Saurabh
    Bray, Freddie
    Lortet-Tieulent, Joannie
    Goodman, Michael
    Jemal, Ahmedin
    [J]. EUROPEAN UROLOGY, 2014, 66 (01) : 59 - 73
  • [8] De Santis M., 2019, EORTC STUDY, V30, p[30986, 191]
  • [9] Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
    Ding, Xiangli
    Chen, Qiaochao
    Yang, Zhao
    Li, Jun
    Zhan, Hui
    Lu, Nihong
    Chen, Min
    Yang, Yanlong
    Wang, Jiansong
    Yang, Delin
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4171 - 4184
  • [10] The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
    Emens, Leisha A.
    Middleton, Gary
    [J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (05) : 436 - 443
123